Oxford Cannabinoid Technologies Holdings Plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Clarissa Ann Sowemimo-Coker
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Maddox House London United Kingdom W1S 2PZ
- IPO Date
- Oct 20, 2021
- Website
- oxcantech.com
- Similar Companies
- Business
- Oxford Cannabinoid Technologies Holdings Plc operates as a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of cannabinoid-based prescription medicines with a primary focus on pain management and other therapeutic conditions. The company's core product portfolio includes lead drug candidates such as OCT461201, a cannabinoid-like new chemical entity in Phase I clinical trials targeting peripheral neuropathies and irritable bowel syndrome; OCT130401, a phytocannabinoid-based inhalation therapy in pre-clinical development for trigeminal neuralgia; and OCT960609, a dual CB1 and CB2 agonist aimed at neuropathic pain indications. Additionally, Oxford Cannabinoid Technologies is developing immunotherapy agents for the treatment of solid tumors. The company leverages a diverse compound library accessed through an exclusive worldwide licensing agreement with Canopy Growth Corporation, encompassing approximately 2,000 compounds including over 500 proprietary derivatives and multiple patent families. Founded in 2017 and headquartered in London, United Kingdom, Oxford Cannabinoid Technologies conducts operations primarily within the UK and engages in pharmaceutical research targeting unmet medical needs related to the endocannabinoid system. The company has focused its portfolio to balance risk, value, and time to market, with ongoing clinical trials designed to achieve regulatory approvals from key agencies like the FDA, MHRA, and EMA. Recent major developments include a strategic pivot in 2023 towards oncology with the identification of a potential first-in-class immunotherapy agent for solid tumors, although this program was subsequently scaled back due to financial constraints to prioritize the lead compound OCT461201. The company has also filed multiple patent applications related to its pipeline assets and maintains an active partnership with Canopy Growth Corporation to co-own intellectual property. Financial and operational challenges culminated in Oxford Cannabinoid Technologies ceasing trading and entering administration as of May 2025, marking a significant downturn for the firm and the broader UK cannabis-biotech sector. Prior to this, the company had received independent valuations supporting its innovative pipeline's commercial potential with expected product launches projected for the latter half of the decade. Oxford Cannabinoid Technologies Holdings Plc serves the pharmaceutical and biotechnology industry segments, targeting markets that require prescription cannabinoid therapies for pain and other chronic conditions. Its R&D activities and partnerships underpin its aim to become a global leader in cannabinoid-based prescription medicines, leveraging advanced scientific techniques to expand understanding and application of cannabinoids in medicine.
British biotech joins LSE exodus
Oxford Cannabinoid Technologies files patent application for pain relief drug
Oxford Cannabinoid appoints CMO Dr Tim Corn to the board
Oxford Cannabinoid Technologies delighted with phase 1 outcome for pain drug
Oxford Cannabinoid Technologies shares jumo 6% on successful completion of phase I study
Oxford Cannabinoid readies for next stage as it safely navigates phase I stduy
Oxford Cannabinoid Technologies completes final dose in phase I trial of lead asset
Oxford Cannabinoid Technologies hails defining year as clinical trials remain on track
Oxford Cannabinoid Technologies takes pain drug into phase I; appoints leading pain expert
Oxford Cannabinoid jumps as firm hints cheaper cancer treatments
Oxford Cannabinoid expands into oncology with potential new cannabinoid-based treatment
Oxford Cannabinoid appoints chief medical officer
US stocks set for lower open as investors eye Fed minutes amid debt ceiling drama
Oxford Cannabinoid rise continues as first clincial trial gets started
Oxford Cannabinoid to start phase 1 trial for pain relief drug
Oxford Cannabinoid Technologies shares spike on CEO appointment and licence renewal
Oxford Cannabinoid Technologies confirms CEO appointment, licence renewal and clinical progress
Oxford Cannabinoid Technologies upbeat ahead of pivotal trial
Oxford Cannabinoid Technologies hails 'milestone' as it submits Phase I trial application for lead programme
Oxford Cannabinoid Technologies issues positive trading and operational update